LIVE Trump says tariffs on Canada, Mexico will go forward on Tuesday Mexico - Delayed Quote • MXN Inovio Pharmaceuticals, Inc. (INO.MX) Follow Compare 40.00 0.00 (0.00%) At close: February 28 at 8:41:37 AM CST Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for INO.MX 1D 5D -8.68% 1M -8.68% 3M -55.56% 6M -68.75% YTD 2.56% 1Y -75.16% 5Y -98.09% All -98.09% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: INO.MX View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments Top Midday Decliners INOVIO Announces Pricing of $30 Million Public Offering INOVIO Announces Proposed Public Offering New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial INOVIO Reports Inducement Grant Under Inducement Plan Inovio Pharmaceuticals Third Quarter 2024 Earnings: US$0.89 loss per share (vs US$1.52 loss in 3Q 2023) Related Tickers ATOS.MX Atossa Therapeutics, Inc. 14.70 -8.13% OCGN.MX Ocugen, Inc. 13.35 0.00% MRNA.MX Moderna, Inc. 624.80 +0.29% ATOS Atossa Therapeutics, Inc. 0.7410 -3.23% OCGN Ocugen, Inc. 0.6051 -7.15% MRNA Moderna, Inc. 30.27 -2.23%